Anebulo Pharmaceuticals, Inc. (ANEB) Insider Trading Activity

NASDAQ$1.09
Market Cap
$44.78M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
443 of 893
Rank in Industry
257 of 510

ANEB Insider Trading Activity

ANEB Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
Sells
$0
0

Related Transactions

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Insider Activity of Anebulo Pharmaceuticals, Inc.

Over the last 12 months, insiders at Anebulo Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Anebulo Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Anebulo Pharmaceuticals, Inc. have bought $5.05M and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,101,010 shares for transaction amount of $10M was made by English Aron R. () on 2024‑12‑23.

List of Insider Buy and Sell Transactions, Anebulo Pharmaceuticals, Inc.

2024-12-23PurchaseEnglish Aron R.
10.1M
30.1255%
$0.99
$10M
+32.00%
2021-12-17PurchaseEnglish Aron R.
400
0.0016%
$6.59
$2,634
-43.79%
2021-12-14PurchaseEnglish Aron R.
412
0.0015%
$5.89
$2,429
-40.48%
2021-12-03PurchaseEnglish Aron R.
4,500
0.0153%
$5.93
$26,685
-42.67%
2021-12-02PurchaseEnglish Aron R.
13,836
0.0441%
$5.30
$73,331
-39.35%
Total: 5

Insider Historical Profitability

<0.0001%
English Aron R.
15467300
37.6473%
$16.86M50
<0.0001%

Historical Insider Profitability vs. Competitors

$2,458,011
109
12.54%
$43.18M
$24,478,755
37
-34.59%
$46.99M
$94,443,856
31
-22.52%
$40.91M
$2,983,776
25
-16.47%
$45.99M
$523,320
24
94.37%
$40.24M
$241,165
22
-16.72%
$41.49M
$26,736,140
20
-18.64%
$52.06M
$20,234,041
17
2.09%
$53.87M
$3,763,566
15
-21.70%
$53.68M
$19,300,035
11
45.88%
$45.4M
$139,855
11
-32.84%
$39.89M
$70,584,874
10
3.97%
$43.88M
$13,595,542
9
-16.74%
$39.65M
$45,000,000
6
-31.22%
$47.95M
Anebulo Pharmaceuticals, Inc.
(ANEB)
$10,105,079
5
-26.86%
$44.78M
$26,254,149
5
49.97%
$48.86M
$49,127
3
-42.90%
$42.21M
$8,997,728
2
-11.16%
$42.67M
$4,030
1
9.14%
$53.08M

ANEB Institutional Investors: Active Positions

Increased Positions13+56.52%205,201+0.91%
Decreased Positions9-39.13%577,289-2.56%
New Positions9New107,452New
Sold Out Positions6Sold Out541,581Sold Out
Total Postitions27+17.39%22M-1.65%

ANEB Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
22Nw, Lp$17,478.0037.73%15.47M00%2025-09-30
Nantahala Capital Management, Llc$3,431.007.41%3.04M00%2025-09-30
Mangrove Partners Im, Llc$2,854.006.16%2.53M00%2025-09-30
Morgan Stanley$451.000.97%399,404+185+0.05%2025-09-30
Vanguard Group Inc$346.000.75%306,540+90,589+41.95%2025-09-30
Geode Capital Management, Llc$197.000.43%174,108-31,612-15.37%2025-09-30
Ikarian Capital, Llc$178.000.39%157,72000%2025-09-30
Renaissance Technologies Llc$32.000.07%28,500+28,500New2025-09-30
Northern Trust Corp$28.000.06%24,393+24,393New2025-09-30
Blackrock, Inc.$27.000.06%24,060+6,847+39.78%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.